WHIM Clinical Study Seek Participants
Research Program will Assess the Safety and Efficacy of a CXCR4 Antagonist
A Phase 2/3 clinical study in patients with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) with an oral CXCR4 antagonist targeting the underlying cause of WHIM is actively recruiting adult patients. Due to the rarity of WHIM, at this stage the study is only being conducted at 3 sites in Seattle, Michigan and Florida. Reasonable travel, lodging and meals costs will be provided for those who are eligible and willing to participate. After completing the study participants may be eligible for continued access to study drug.
The study is registered on ClinicalTrials.gov under Identifier: NCT030005327. URL: https://clinicaltrials.gov/ct2/show/NCT03005327?term=X4&rank=2
Most of these patients have chronic neutropenia and may have a PID with unknown cause. The study sponsor, X4 Pharmaceuticals, is offering free genetic testing of the CXCR4 gene for those who meet certain criteria to rule in or out WHIM.
If you have patients that may be eligible for referral to the study or if you are interested in having any patients suspected to have WHIM genetically tested then please contact X4 Pharmaceuticals at patientinfo@X4pharma.com or contact Ramsey Johnson in Clinical Operations at 857-529-8308.